Vincerx Pharma, Inc. (VINC) Misses Q3 EPS by 25c

Vincerx Pharma, Inc. (NASDAQ: VINC) reported Q3 EPS of ($0.80), $0.25 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Vincerx Pharma, Inc. (VINC) click here.

You May Also Be Interested In

• AI and memory not a classic bubble, but future returns uncertain - strategist
• Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens
• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance